The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Montelukast for treating seasonal allergic rhinitis: a randomized, double‐blind, placebo‐controlled trial performed in the spring
Abstract
Summary: Background Cysteinyl leukotrienes are important proinflammatory mediators believed to have a role in allergic rhinitis. Objective This multicentre, randomized, double‐blind, placebo‐ and active‐controlled trial evaluated the effectiveness and tolerability of montelukast, a cysteinyl leukotriene receptor antagonist, for treating patients with seasonal allergic rhinitis. Methods After a 3‐ to 5‐day, single‐blind placebo run‐in period, 1302 male and female patients (aged 15–81 years) with active allergic rhinitis symptoms were randomly assigned to receive montelukast 10 mg (n = 348), loratadine 10 mg (n = 602), or placebo (n = 352) administered once daily at bedtime for 2 weeks during the spring allergy season. Results Mean patient characteristics and symptom scores at baseline were similar for the three treatment groups. The primary end‐point, daytime nasal symptoms score (mean of nasal congestion, rhinorrhea, nasal pruritus, and sneezing scores; 0–3 scale), improved from baseline during treatment by (least squares mean, 95% confidence interval) − 0.37 (− 0.43, − 0.31), − 0.47 (− 0.52, − 0.43), and − 0.24 (− 0.29, − 0.18) in the montelukast, loratadine, and placebo groups, respectively (P ≤ 0.001 comparing each active treatment with placebo). Mean changes from baseline in all other diary‐based scores, including night‐time and eye symptom scores, were significantly greater for each active treatment than for placebo. The rhinoconjunctivitis quality of life overall score improved significantly with montelukast and with loratadine as compared with placebo. Montelukast and loratadine showed a safety profile comparable to that of placebo. Conclusion Montelukast is well tolerated and provides improvements in daytime and night‐time symptoms, as well as quality of life parameters, for patients with seasonal allergic rhinitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Strachan, D., Sibbald, B., Weiland, S., Ait‐Khaled, N., Anabwani, G., Anderson, H. R., Asher, M. I., Beasley, R., Bjorksten, B., Burr, M., et al. (1997) · Pediatric Allergy and Immunology · doi:10.1111/j.1399-3038.1997.tb00156.x · Cited by 654
Weiner, J. M., Abramson, M. J., & Puy, R. M. (1998) · BMJ · doi:10.1136/bmj.317.7173.1624 · Cited by 527
Bentley, A. M., Jacobson, M. R., Cumberworth, V., Barkans, J. R., Moqbel, R., Schwartz, L. B., Irani, A.-M. A., Kay, A. B., & Durham, S. R. (1992) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(92)90444-7 · Cited by 274
Cited by
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*
Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J., Fokkens, W. J., Togias, A., Zuberbier, T., Baena‐Cagnani, C. E., Canonica, G. W., Van Weel, C., et al. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01620.x · Cited by 4,729
The diagnosis and management of rhinitis: An updated practice parameter
WALLACE, D., DYKEWICZ, M., BERNSTEIN, D., BLESSINGMOORE, J., COX, L., KHAN, D., LANG, D., NICKLAS, R., OPPENHEIMER, J., & PORTNOY, J. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.06.003 · Cited by 1,096
Peters-Golden, M., & Henderson, W. R. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071371 · Cited by 1,013
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
Metadata
- Authors
- Philip, G., Malmstrom, K., Hampel, F. C., Weinstein, S. F., LaForce, C. F., Ratner, P. H., Malice, M. ‐., Reiss, T. F., & for the Montelukast Spring Rhinitis Study Group
- Venue
- Clinical & Experimental Allergy
- Publisher
- Wiley
- Published
- 2002-07
- Volume
- 32
- Issue
- 7
- Pages
- 1020-1028
- ISSN
- 0954-7894 (ISSN-L)
- 1365-2222
- OpenAlex
- W2087519128
- Cited by
- 240
- References
- 3
- FWCI
- 11.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Montelukast for treating seasonal allergic rhinitis: a randomized, double‐blind, placebo‐controlled trial performed in the spring. https://app.cochat.ai/papers/10.1046/j.1365-2222.2002.01422.x
- The paper
- Philip, G., Malmstrom, K., Hampel, F. C., Weinstein, S. F., LaForce, C. F., Ratner, P. H., Malice, M. ‐., Reiss, T. F., & for the Montelukast Spring Rhinitis Study Group. (2002). Montelukast for treating seasonal allergic rhinitis: a randomized, double‐blind, placebo‐controlled trial performed in the spring. Clinical & Experimental Allergy. https://doi.org/10.1046/j.1365-2222.2002.01422.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.